The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Agenus; Boston Scientific (I); LFB Biotechnologies
Stock and Other Ownership Interests - Agenus; Alnylam; Boston Scientific (I)
AGEN1181, a clinical stage Fc-engineered anti-CTLA-4 antibody with improved therapeutic potential for the treatment of patients with advanced malignancies.
 
Steven O'Day
Honoraria - Agenus; Biothera; Bristol-Myers Squibb; ImaginAb; Merck; RadImmune
Consulting or Advisory Role - Agenus; Biothera; Bristol-Myers Squibb; ImaginAb; Merck; RadImmune
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Agenus (Inst); Amgen (Inst); Biothera (Inst); Bristol-Myers Squibb (Inst); Exicure (Inst); Genocea Biosciences (Inst); Incyte (Inst); Merck (Inst); Ultimovacs (Inst)
Travel, Accommodations, Expenses - Agenus; Bristol-Myers Squibb; Caris MPI; ImaginAb; Merck
 
Chethan Ramamurthy
No Relationships to Disclose
 
Andrea J. Bullock
Stock and Other Ownership Interests - Amgen; Johnson & Johnson; Medtronic
Consulting or Advisory Role - Eisai; Exelixis; Halozyme
 
Anthony B. El-Khoueiry
Honoraria - Agenus; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Eisai; EMD Serono; Exelixis; Gilead Sciences; Merck; Pieris Pharmaceuticals; Roche/Genentech
Consulting or Advisory Role - Agenus; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Eisai; EMD Serono; Exelixis; Gilead Sciences; Merck; Pieris Pharmaceuticals; Roche
Research Funding - Astex Pharmaceuticals; AstraZeneca; Merck
 
Lernik Ohanjanian
Employment - Agenus
 
Anna Wijatyk
Employment - Agenus; Shire
Stock and Other Ownership Interests - Agenus; Shire
Travel, Accommodations, Expenses - Agenus; Shire
 
Waldo Ignacio Ortuzar Feliu
Employment - Agenus
Travel, Accommodations, Expenses - Agenus
 
Irina Shapiro
Employment - Agenus; EMD Serono
Stock and Other Ownership Interests - Agenus; EMD Serono/Merck
Patents, Royalties, Other Intellectual Property - MIT
 
Marek Ancukiewicz
No Relationships to Disclose
 
Dhan Chand
Employment - Agenus
Stock and Other Ownership Interests - Agenus
Patents, Royalties, Other Intellectual Property - Agenus
 
Jennifer Buell
No Relationships to Disclose
 
Michael S. Gordon
Stock and Other Ownership Interests - BeckonCall; Caremission; WCCT Global
Consulting or Advisory Role - Agenus; Castle Biosciences; Daiichi Sankyo; Deciphera; Imaging Endpoints; Neon Therapeutics; RedHill Biopharma; Salarius Pharmaceuticals; TRACON Pharma
Research Funding - AADi (Inst); Abbvie (Inst); Acetylon Pharmaceuticals (Inst); Aduro Biotech (Inst); Advaxis (Inst); Agenus (Inst); Amal Therapeutics (Inst); Amgen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Astellas Pharma (Inst); Athenex (Inst); Ayala Pharmaceuticals (Inst); BeiGene (Inst); Beigene (Inst); BiolineRx (Inst); BioNTech (Inst); Blueprint Medicines (Inst); Calithera Biosciences (Inst); CanBas (Inst); cantex (Inst); Caris Centers of Excellence (Inst); Celgene (Inst); Celldex (Inst); Corcept Therapeutics (Inst); Corcept Therapeutics (Inst); CytomX Therapeutics (Inst); Deciphera (Inst); Driver Group (Inst); Endocyte (Inst); ESSA (Inst); FibroGen (Inst); Five Prime Therapeutics (Inst); Fujifilm (Inst); Fujifilm (Inst); Genentech/Roche (Inst); Genocea Biosciences (Inst); Genzada Pharmaceuticals (Inst); Genzada Pharmaceuticals (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Halozyme (Inst); Helix BioPharma (Inst); Hengrui Therapeutics (Inst); IgM Biosciences (Inst); ImaginAb (Inst); ImmuneSensor Therapeutics (Inst); Inanovate (Inst); Incyte (Inst); Inhibrx (Inst); Lilly (Inst); Lilly/ImClone (Inst); MabVax (Inst); Macrogenics (Inst); MedImmune (Inst); Merck Serono (Inst); Merrimack (Inst); Millennium (Inst); Minneamrita Therapeutics (Inst); Molecular Partners (Inst); Nektar (Inst); Nektar (Inst); Neon Therapeutics (Inst); Neon Therapeutics (Inst); Novartis (Inst); Novartis (Inst); Novita Pharmaceuticals (Inst); OncoMed (Inst); Pfizer (Inst); Pfizer (Inst); Phoenix Biotech (Inst); Plexxikon (Inst); Proderm IQ (Inst); Revolution Medicines (Inst); Salarius Pharmaceuticals (Inst); Samumed (Inst); Seagen (Inst); Sirtex Medical (Inst); Strategia Therapeutics (Inst); Syndax (Inst); Syndax (Inst); SynDevRx (Inst); Syros Pharmaceuticals (Inst); tesaro (Inst); Tokai Pharmaceuticals (Inst); Tolero Pharmaceuticals (Inst); Toray Industries (Inst); TRACON Pharma (Inst); Trovagene (Inst); TTC Oncology (Inst); Verastem (Inst)
Patents, Royalties, Other Intellectual Property - Patient on patient selection for Clinical Trials